Section 37(1) business deduction: pharmaceutical sales promotion and medical conference were held allowable despite MCI-based objections.

Regulatory provisions governing medical practitioners cannot be extended to a pharmaceutical company to deny deduction under section 37(1) unless the assessee itself is shown to have incurred expenditure for an offence or for a purpose prohibited by law. Sales promotion expenses on articles distributed to stockists, distributors, dealers, customers and doctors were treated as ordinary business expenditure, because the Medical Council regulations apply to registered medical practitioners and CBDT Circular No. 5/2012 could not enlarge their scope. Medical conference expenditure for organising and supporting doctors' conferences was also held allowable on the same basis, as no applicable statutory prohibition against the assessee was shown.

---

---

Issues: (i) Whether sales promotion expenses incurred by a pharmaceutical company on articles distributed to stockists, distributors, dealers, customers, and doctors were hit by Explanation 1 to section 37(1) of the Income-tax Act, 1961 on the basis of MCI regulations and CBDT Circular No. 5/2012. (ii) Whether medical conference expenditure incurred for organising and supporting conferences for doctors was similarly inadmissible as being in violation of the MCI regulations and thus prohibited by law.

Issue (i): Whether sales promotion expenses incurred by a pharmaceutical company on articles distributed to stockists, distributors, dealers, customers, and doctors were hit by Explanation 1 to section 37(1) of the Income-tax Act, 1961 on the basis of MCI regulations and CBDT Circular No. 5/2012.

Analysis: The expenditure was examined in the light of section 37(1) and its Explanation 1, the Indian Medical Council Act, 1956, the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, and CBDT Circular No. 5/2012. It was held that the MCI regulations are directed at the conduct of registered medical practitioners and do not govern pharmaceutical companies. The circular could not enlarge the scope of the regulations or create a fresh disallowance in the absence of enabling statutory authority. The earlier coordinate bench decisions in the assessee's own case and similar cases were followed.

Conclusion: The sales promotion expenses were allowable and the disallowance was deleted. The finding is in favour of the assessee.

Issue (ii): Whether medical conference expenditure incurred for organising and supporting conferences for doctors was similarly inadmissible as being in violation of the MCI regulations and thus prohibited by law.

Analysis: The same statutory framework was applied. The expenditure on medical conferences was treated as part of business promotion and awareness building in the pharmaceutical business. Since the MCI regulations regulate medical practitioners and not the assessee-company, and since no statutory prohibition applicable to the assessee was shown, the expenditure was not regarded as an offence or as prohibited by law within the meaning of Explanation 1 to section 37(1). The earlier Tribunal view in the assessee's favour was followed.

Conclusion: The medical conference expenditure was held to be allowable and the disallowance was deleted. The finding is in favour of the assessee.

Final Conclusion: The assessee succeeded on both disputed disallowances, and the revenue's objections failed because the impugned expenses were held to be ordinary business expenditure not hit by the statutory bar under section 37(1).

Ratio Decidendi: Regulatory provisions governing medical practitioners cannot be extended to a pharmaceutical company so as to deny deduction under section 37(1) unless the assessee itself is shown to have incurred expenditure for an offence or for a purpose prohibited by law under an applicable statutory prohibition.

---